onebiosciences.fr

What It Is

One Biosciences is a French precision oncology company positioned around bringing AI-driven, clinical-grade single-cell analysis into clinical practice. Its core claim is that traditional bulk sequencing smooths over cellular heterogeneity within tumors, while the company uses FFPE or frozen samples for single-cell profiling, generates high-quality single-cell maps, and delivers clinician-ready reports in under two weeks.

Core Capabilities

Based on the information on its website, the platform is designed for tumor biopsy samples and emphasizes the ability to work under real clinical sample conditions, rather than only in research settings that rely on large volumes of fresh tissue. Its capabilities cover single-cell, single-nuclei, and multi-omics data generation, with the goal of helping physicians and pharmaceutical companies understand the cellular heterogeneity that drives cancer complexity. AI is mainly used for single-cell data analysis, map construction, and insight generation; the team background also mentions experience in deep learning, generative models, LLMs, data governance, and large-scale genomics infrastructure. However, the website does not disclose specific model architectures, training data scale, performance metrics, or algorithm validation details.

Pricing and Delivery

The website does not publish standard packages, per-sample pricing, or subscription models, nor does it show a free trial. Its business model appears to be more project- or partnership-based, primarily serving pharma, biotech, and clinical institutions across scenarios such as patient selection, treatment response prediction, drug development, clinical trial optimization, and “trial rescue.”

Pros and Cons

The main advantage is its clear technical focus: it targets the high-value problem of tumor heterogeneity, supports FFPE/frozen samples, and promises clinically readable reports within two weeks, making it closely aligned with real-world diagnosis, treatment, and clinical trial needs. The team also has relevant backgrounds from Institut Curie, Gustave Roussy, Foundation Medicine, and similar organizations, giving it relatively strong academic and industry credibility.

The drawback is limited transparency. The website does not explain its regulatory certification status, indication boundaries, sample failure rates, report examples, AI explainability, API availability, or integration methods with hospital systems. On data privacy, it only shows legal and DPO/data governance role descriptions, without more specific information on compliance frameworks or data hosting.

Who It’s For and Access from China

It is better suited to pharmaceutical companies, oncology clinical research teams, and precision medicine organizations, rather than individual users or general AI tool users. Access from China is unclear; as the website belongs to a French company, there is no textual basis for determining whether it has local laboratories, logistics, compliance capabilities, or report delivery support in China.